Immunodiagnostics Market Forecast to 2030 - Global Analysis by Product [Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others], Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others), and Geography
The immunodiagnostics market size is expected to reach US$ 34,487.80 million by 2030 from US$ 19,218.89 million in 2022; it is estimated to record a CAGR of 7.6% from 2022 to 2030.
Immunodiagnostics is referred as a diagnostic methodology that primarily uses antigen-antibody reaction as its primary means of detection. Antibodies specific for a desired antigen can be conjugated with a radiolabel, fluorescent label, or color-forming enzyme and are used as a probe to detect it. The speed, accuracy and simplicity of such tests has led to the development of rapid techniques for the diagnosis of disease, microbes and even illegal drugs in vivo.
Point-of-care testing (POCT) has become critical to patient-centric healthcare due to the need for rapid diagnostic results to determine accurate and faster treatments. A shift from centralized point-of-care testing to decentralized testing has resulted in easy access to these diagnostics. Immunoassay testing helps monitor chronic conditions and detect pathogens, such as bacteria and viruses. Advanced point-of-care devices enable rapid screening of up to three components from a single sample. Also, the point-of-care diagnostics (POCD) inclined toward mobile healthcare (mH) smart devices could revolutionize personalized healthcare monitoring and management, paving the way for next-generation POCTs. The management of infectious diseases can be significantly improved by POCTs, particularly in developing countries where access to timely medical care is challenging and healthcare infrastructure is outdated and sparse. Additionally, the technologically developed diagnostic kits leading to fewer manual errors propel the immunodiagnostics market. Several market players are developing innovative immunodiagnostic products. For instance, Thermo Fisher Scientific has developed immunodiagnostic products such as enzyme-linked immunoassay (ELISA) reagents and buffers, antibodies and detection probes, linking mechanisms, blocking buffers and detergents, detection substrates, and capture surfaces, as well as services such as bioconjugation and detection. Further, in September 2020, Roche launched the SARS-CoV-2 Rapid Antigen Test, which is used in POC settings to help healthcare professionals identify the infection within 15 minutes in people suspected of carrying the virus.
In April 2021, DiaSorin introduced the LIAISON IQ, a new immunodiagnostic Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics for countries accepting the CE Mark. Using a fingerstick of human capillary blood, this test for the LIAISON IQ identifies specific IgG antibodies against SARS-CoV-2 Spike Protein in 10 minutes.
In April 2021, Chembio Diagnostics, Inc. launched an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test for use in traditional and decentralized testing settings. The rapid immunoassay test requires no instrumentation and produces results in 15 minutes.
WHO applauded the test kit developers for efforts taken to innovate and respond to the masses’ requirements during the COVID-19 crisis. According to the American Society for Clinical Pathology, in March 2020, the Cepheid Xpert Xpress SARS-CoV-2 test became the first POC COVID-19 detection assay to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).
Likewise, the use of immunodiagnostics in cancer treatment is increasing. In oncology, an immunodiagnostic test can confirm the presence of a solid tumor by detecting known tumor-associated antigens or antibodies. These advantages and indications are driving the immunodiagnostics market growth.
Based on product, the immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. Based on clinical indication, the market is divided into infectious diseases, Hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. By end user, the immunodiagnostics market is categorized into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. Geographically, the immunodiagnostics market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), Industrial Biotechnology Leadership Forum (IBLF), International Diabetes Federation (IDF), and Ministry of Health and Prevention (MoHaP) are a few key primary and secondary sources referred to while preparing the report on the immunodiagnostics market.
Based on product, the immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held the largest immunodiagnostics market share in 2022. The chemiluminescence immunoassays (CLIA) segment is anticipated to record a significant growth rate during the forecast period. Enzyme-linked immunosorbent assay (ELISA) frequently measures antibodies, proteins, antigens, and glycoproteins in biological samples. ELISA is used for HIV diagnosis, pregnancy tests, and cytokine or soluble receptor measurement (from cell supernatant or serum). It has replaced radioimmunoassay (RIA) to become one of the most common and reliable diagnostic tools. Moreover, the ELISA technique advancement led to the development of quantitative PCR, fluorogenic, and electro-chemiluminescent reporters to generate signals. Further, ELISA, along with lateral flow immunoassays, was widely used during the COVID-19 pandemic to identify individuals having antibodies developed against SARS-CoV-2, thus driving the immunodiagnostics market growth.
Immunodiagnostics Market: Competitive Landscape and Key Developments
Abbott Laboratories, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Danaher Corp, Thermo Fisher Scientific Inc, PerkinElmer Inc, Shenzhen Mindray Bio-Medical Electronics Co Ltd, bioMerieux SA, Svar Life Science AB, and Siemens Healthineers AG are a few key companies operating in the immunodiagnostics market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name.
A few of the recent developments in the global immunodiagnostics market are mentioned below:
• In May 2023, Thermo Fisher Scientific announced that the US FDA had cleared its immunoassays, B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers. These immunoassays assess risks and clinical management of preeclampsia, a severe pregnancy complication.
• In April 2023, Thermo Fisher Scientific announced a partnership with ALPCO-GeneProof, a global leader in diagnostics. The partnership has helped to bring TaqPath Menu | GeneProof PCR kits into the market.
• In July 2022, Abbott Diagnostics announced its participation in American Association for Clinical Chemistry (AACC) 2022. In the exhibition, the company demonstrated its diagnostics systems and analyzers.
• In May 2022, Roche and The Global Fund to Fight AIDS, Tuberculosis and Malaria joined forces to build and strengthen diagnostic capacity and pandemic preparedness in low-and middle-income countries fighting against HIV and tuberculosis (TB).
• In September 2022, Mindray launched the ToRCH Panel. With this panel, the company offers high-quality assays to meet different clinical needs. Mindray ToRCH kits support diverse sample types with less quality controls and sample volumes, which ensures great ease and convenience during clinical detection.
• In May 2022, Thermo Fisher Scientific announced that the Phadia 2500+ series of instruments are available for autoimmune testing in the US. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.
• In July 2022, Roche announced the launch of the Elecsys HCV Duo immunoassay in countries that accept the CE Mark. The Elecsys HCV Duo immunoassay enables a significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.
Immunodiagnostics is referred as a diagnostic methodology that primarily uses antigen-antibody reaction as its primary means of detection. Antibodies specific for a desired antigen can be conjugated with a radiolabel, fluorescent label, or color-forming enzyme and are used as a probe to detect it. The speed, accuracy and simplicity of such tests has led to the development of rapid techniques for the diagnosis of disease, microbes and even illegal drugs in vivo.
Point-of-care testing (POCT) has become critical to patient-centric healthcare due to the need for rapid diagnostic results to determine accurate and faster treatments. A shift from centralized point-of-care testing to decentralized testing has resulted in easy access to these diagnostics. Immunoassay testing helps monitor chronic conditions and detect pathogens, such as bacteria and viruses. Advanced point-of-care devices enable rapid screening of up to three components from a single sample. Also, the point-of-care diagnostics (POCD) inclined toward mobile healthcare (mH) smart devices could revolutionize personalized healthcare monitoring and management, paving the way for next-generation POCTs. The management of infectious diseases can be significantly improved by POCTs, particularly in developing countries where access to timely medical care is challenging and healthcare infrastructure is outdated and sparse. Additionally, the technologically developed diagnostic kits leading to fewer manual errors propel the immunodiagnostics market. Several market players are developing innovative immunodiagnostic products. For instance, Thermo Fisher Scientific has developed immunodiagnostic products such as enzyme-linked immunoassay (ELISA) reagents and buffers, antibodies and detection probes, linking mechanisms, blocking buffers and detergents, detection substrates, and capture surfaces, as well as services such as bioconjugation and detection. Further, in September 2020, Roche launched the SARS-CoV-2 Rapid Antigen Test, which is used in POC settings to help healthcare professionals identify the infection within 15 minutes in people suspected of carrying the virus.
In April 2021, DiaSorin introduced the LIAISON IQ, a new immunodiagnostic Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics for countries accepting the CE Mark. Using a fingerstick of human capillary blood, this test for the LIAISON IQ identifies specific IgG antibodies against SARS-CoV-2 Spike Protein in 10 minutes.
In April 2021, Chembio Diagnostics, Inc. launched an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test for use in traditional and decentralized testing settings. The rapid immunoassay test requires no instrumentation and produces results in 15 minutes.
WHO applauded the test kit developers for efforts taken to innovate and respond to the masses’ requirements during the COVID-19 crisis. According to the American Society for Clinical Pathology, in March 2020, the Cepheid Xpert Xpress SARS-CoV-2 test became the first POC COVID-19 detection assay to receive Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).
Likewise, the use of immunodiagnostics in cancer treatment is increasing. In oncology, an immunodiagnostic test can confirm the presence of a solid tumor by detecting known tumor-associated antigens or antibodies. These advantages and indications are driving the immunodiagnostics market growth.
Based on product, the immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. Based on clinical indication, the market is divided into infectious diseases, Hepatitis+HIV, endocrinology, gastrointestinal, metabolics, and others. By end user, the immunodiagnostics market is categorized into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. Geographically, the immunodiagnostics market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
The World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), Industrial Biotechnology Leadership Forum (IBLF), International Diabetes Federation (IDF), and Ministry of Health and Prevention (MoHaP) are a few key primary and secondary sources referred to while preparing the report on the immunodiagnostics market.
Based on product, the immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held the largest immunodiagnostics market share in 2022. The chemiluminescence immunoassays (CLIA) segment is anticipated to record a significant growth rate during the forecast period. Enzyme-linked immunosorbent assay (ELISA) frequently measures antibodies, proteins, antigens, and glycoproteins in biological samples. ELISA is used for HIV diagnosis, pregnancy tests, and cytokine or soluble receptor measurement (from cell supernatant or serum). It has replaced radioimmunoassay (RIA) to become one of the most common and reliable diagnostic tools. Moreover, the ELISA technique advancement led to the development of quantitative PCR, fluorogenic, and electro-chemiluminescent reporters to generate signals. Further, ELISA, along with lateral flow immunoassays, was widely used during the COVID-19 pandemic to identify individuals having antibodies developed against SARS-CoV-2, thus driving the immunodiagnostics market growth.
Immunodiagnostics Market: Competitive Landscape and Key Developments
Abbott Laboratories, F. Hoffmann-La Roche Ltd, DiaSorin SpA, Danaher Corp, Thermo Fisher Scientific Inc, PerkinElmer Inc, Shenzhen Mindray Bio-Medical Electronics Co Ltd, bioMerieux SA, Svar Life Science AB, and Siemens Healthineers AG are a few key companies operating in the immunodiagnostics market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name.
A few of the recent developments in the global immunodiagnostics market are mentioned below:
• In May 2023, Thermo Fisher Scientific announced that the US FDA had cleared its immunoassays, B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers. These immunoassays assess risks and clinical management of preeclampsia, a severe pregnancy complication.
• In April 2023, Thermo Fisher Scientific announced a partnership with ALPCO-GeneProof, a global leader in diagnostics. The partnership has helped to bring TaqPath Menu | GeneProof PCR kits into the market.
• In July 2022, Abbott Diagnostics announced its participation in American Association for Clinical Chemistry (AACC) 2022. In the exhibition, the company demonstrated its diagnostics systems and analyzers.
• In May 2022, Roche and The Global Fund to Fight AIDS, Tuberculosis and Malaria joined forces to build and strengthen diagnostic capacity and pandemic preparedness in low-and middle-income countries fighting against HIV and tuberculosis (TB).
• In September 2022, Mindray launched the ToRCH Panel. With this panel, the company offers high-quality assays to meet different clinical needs. Mindray ToRCH kits support diverse sample types with less quality controls and sample volumes, which ensures great ease and convenience during clinical detection.
• In May 2022, Thermo Fisher Scientific announced that the Phadia 2500+ series of instruments are available for autoimmune testing in the US. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.
• In July 2022, Roche announced the launch of the Elecsys HCV Duo immunoassay in countries that accept the CE Mark. The Elecsys HCV Duo immunoassay enables a significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.
1. INTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Immunodiagnostics Market – by Product
1.3.2 Global Immunodiagnostics Market – by Clinical Indication
1.3.3 Global Immunodiagnostics Market – by End User
1.3.4 Global Immunodiagnostics Market – by Geography
2. IMMUNODIAGNOSTICS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. IMMUNODIAGNOSTICS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.5 Middle East & Africa PEST Analysis
4.2.6 South & Central America PEST Analysis
4.3 Expert’s Opinion
5. IMMUNODIAGNOSTICS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Prevalence of Infectious Diseases
5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis
6. IMMUNODIAGNOSTICS MARKET – GLOBAL ANALYSIS
6.1 Global Immunodiagnostics Market Revenue Forecast and Analysis
6.2 Global Immunodiagnostics Market, by Geography – Forecast and Analysis
6.3 Market Positioning of Key Players
7. IMMUNODIAGNOSTICS MARKET ANALYSIS – BY PRODUCT
7.1 Overview
7.2 Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
7.3.1 Overview
7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
7.4.1 Overview
7.4.2 Chemiluminescence Immunoassays (CLIA): Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.3 Vitamin D Assay
7.4.3.1 Overview
7.4.3.2 Vitamin D Assay: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.4 HIV Detection
7.4.4.1 Overview
7.4.4.2 HIV Detection: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.5 HIV Ag/Ab Combo assay
7.4.5.1 Overview
7.4.5.2 HIV Ag/Ab Combo Assay: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.6 Other Tests
7.4.6.1 Overview
7.4.6.2 Other Tests: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
7.5.1 Overview
7.5.2 Radioimmunoassays (RIA): Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8. IMMUNODIAGNOSTICS MARKET ANALYSIS – CLINICAL INDICATION
8.1 Overview
8.2 Global Immunodiagnostics Market Share by Clinical Indication - 2022 & 2030 (%)
8.3 Infectious Diseases:
8.3.1 Overview
8.3.2 Infectious Diseases: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 COVID-19
8.3.2.1.1 Overview
8.3.2.1.2 COVID-19: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.2 Tuberculosis
8.3.2.2.1 Overview
8.3.2.2.2 Tuberculosis: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.3 Lyme
8.3.2.3.1 Overview
8.3.2.3.2 Lyme: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.4 Infection Management
8.3.2.4.1 Overview
8.3.2.4.2 Infection Management: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.5 Zika
8.3.2.5.1 Overview
8.3.2.5.2 Zika: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.6 Treponema
8.3.2.6.1 Overview
8.3.2.6.2 Treponema: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.7 TORCH
8.3.2.7.1 Overview
8.3.2.7.2 TORCH: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.8 Measles and Mumps
8.3.2.8.1 Overview
8.3.2.8.2 Measles and Mumps: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.9 VZV
8.3.2.9.1 Overview
8.3.2.9.2 VZV: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.10 EBV
8.3.2.10.1 Overview
8.3.2.10.2 EBV: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
8.4.1 Overview
8.4.2 Hepatitis+HIV: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
8.5.1 Overview
8.5.2 Gastrointestinal: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolics: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
8.7.1 Overview
8.7.2 Endocrinology: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.3 Hypertension
8.7.3.1 Overview
8.7.3.2 Hypertension: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.4 Growth
8.7.4.1 Overview
8.7.4.2 Growth: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.5 Diabetes
8.7.5.1 Overview
8.7.5.2 Diabetes: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.6 Thyroid
8.7.6.1 Overview
8.7.6.2 Thyroid: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.7 Reproductive Endocrinology
8.7.7.1 Overview
8.7.7.2 Reproductive Endocrinology: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9. IMMUNODIAGNOSTICS MARKET ANALYSIS – END USER
9.1 Overview
9.2 Global Immunodiagnostics Market Share by End User - 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
9.6.1 Overview
9.6.2 Academic and Research Institutes: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
10. IMMUNODIAGNOSTICS MARKET – REVENUE AND FORECAST TO 2030 – GEOGRAPHIC ANALYSIS
10.1 North America: Immunodiagnostics Market
10.1.1 Overview
10.1.2 North America: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3 North America: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.3.1 North America: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.4 North America: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.1.4.1 North America: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.4.2 North America: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.5 North America: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.5.1 US: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.1 Overview
10.1.5.1.2 US: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.3 US: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.5.1.3.1 US: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.4 US: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.4.1 US: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.4.2 US: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.5 US: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.5.2 Canada: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.1 Overview
10.1.5.2.2 Canada: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.3 Canada: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.5.2.3.1 Canada: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.4 Canada: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.4.1 Canada: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.4.2 Canada: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.5 Canada: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.5.3 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.1 Overview
10.1.5.3.2 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.3 Mexico: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.5.3.3.1 Mexico: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.4 Mexico: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.4.1 Mexico: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.4.2 Mexico: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.5 Mexico: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2 Europe: Immunodiagnostics Market
10.2.1 Overview
10.2.2 Europe: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.2.3 Europe: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.3.1 Europe: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.4 Europe: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.2.4.1 Europe: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.4.2 Europe: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5 Europe: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.1 UK: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.1 Overview
10.2.5.1.2 UK: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.3 UK: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.1.3.1 UK: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.4 UK: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.4.1 UK: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.4.2 UK: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.5 UK: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.2 Germany: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.1 Overview
10.2.5.2.2 Germany: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.3 Germany: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.2.3.1 Germany: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.4 Germany: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.4.1 Germany: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.4.2 Germany: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.5 Germany: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.3 France: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.1 Overview
10.2.5.3.2 France: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.3 France: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.3.3.1 France: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.4 France: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.4.1 France: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.4.2 France: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.5 France: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.4 Italy: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.1 Overview
10.2.5.4.2 Italy: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.3 Italy: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.4.3.1 Italy: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.4 Italy: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.4.1 Italy: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.4.2 Italy: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.5 Italy: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.5 Spain: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.1 Overview
10.2.5.5.2 Spain: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.3 Spain: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.5.3.1 Spain: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.4 Spain: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.4.1 Spain: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.4.2 Spain: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.5 Spain: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.6 Rest of Europe: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.1 Overview
10.2.5.6.2 Rest of Europe: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.3 Rest of Europe: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.6.3.1 Rest of Europe: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.4 Rest of Europe: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.4.1 Rest of Europe: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.4.2 Rest of Europe: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.5 Rest of Europe: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3 Asia Pacific: Immunodiagnostics Market
10.3.1 Overview
10.3.2 Asia Pacific: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.3.3 Asia Pacific: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.3.1 Asia Pacific: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.4 Asia Pacific: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.3.4.1 Asia Pacific: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.4.2 Asia Pacific: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5 Asia Pacific: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.1 China: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.1 Overview
10.3.5.1.2 China: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.3 China: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.1.3.1 China: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.4 China: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.4.1 China: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.4.2 China: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.5 China: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.2 Japan: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.1 Overview
10.3.5.2.2 Japan: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.3 Japan: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.2.3.1 Japan: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.4 Japan: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.4.1 Japan: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.4.2 Japan: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.5 Japan: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.3 India: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.1 Overview
10.3.5.3.2 India: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.3 India: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.3.3.1 India: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.4 India: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.4.1 India: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.4.2 India: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.5 India: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.4 Australia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.1 Overview
10.3.5.4.2 Australia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.3 Australia: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.4.3.1 Australia: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.4 Australia: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.4.1 Australia: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.4.2 Australia: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.5 Australia: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.5 South Korea: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.1 Overview
10.3.5.5.2 South Korea: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.3 South Korea: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.5.3.1 South Korea: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.4 South Korea: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.4.1 South Korea: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.4.2 South Korea: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.5 South Korea: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.6 Rest of Asia Pacific: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.1 Overview
10.3.5.6.2 Rest of Asia Pacific: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.3 Rest of Asia Pacific: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.6.3.1 Rest of Asia Pacific: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.4 Rest of Asia Pacific: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.4.1 Rest of Asia Pacific: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.4.2 Rest of Asia Pacific: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.5 Rest of Asia Pacific: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4 Middle East & Africa: Immunodiagnostics Market
10.4.1 Overview
10.4.2 Middle East & Africa: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.4.3 Middle East & Africa: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.3.1 Middle East & Africa: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.4 Middle East & Africa: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.4.4.1 Middle East & Africa: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.4.2 Middle East & Africa: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5 Middle East & Africa: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4.5.1 UAE: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.1 Overview
10.4.5.1.2 UAE: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.3 UAE: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.5.1.3.1 UAE: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.4 UAE: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.4.1 UAE: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.4.2 UAE: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.5 UAE: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4.5.2 Saudi Arabia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.1 Overview
10.4.5.2.2 Saudi Arabia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.3 Saudi Arabia: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.5.2.3.1 Saudi Arabia: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.4 Saudi Arabia: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.4.1 Saudi Arabia: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.4.2 Saudi Arabia: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.5 Saudi Arabia: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4.5.3 South Africa: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.1 Overview
10.4.5.3.2 South Africa: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.3 South Africa: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.5.3.3.1 South Africa: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.4 South Africa: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.4.1 South Africa: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.4.2 South Africa: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.5 South Africa: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4.5.4 Rest of Middle East & Africa: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.1 Overview
10.4.5.4.2 Rest of Middle East & Africa: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.3 Rest of Middle East & Africa: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.5.4.3.1 Rest of Middle East & Africa: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.4 Rest of Middle East & Africa: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.4.1 Rest of Middle East & Africa: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.4.2 Rest of Middle East & Africa: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.5 Rest of Middle East & Africa: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.5 South & Central America: Immunodiagnostics Market
10.5.1 Overview
10.5.2 South & Central America: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.5.3 South & Central America: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.5.3.1 South & Central America: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.5.4 South & Central America: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.5.4.1 South & Central America: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.5.4.2 South & Central America: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.5.5 South & Central America: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.5.5.1 Brazil: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.1 Overview
10.5.5.1.2 Brazil: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.3 Brazil: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.5.5.1.3.1 Brazil: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.4 Brazil: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.4.1 Brazil: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.4.2 Brazil: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.5 Brazil: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.5.5.2 Argentina: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.1 Overview
10.5.5.2.2 Argentina: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.3 Argentina: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.5.5.2.3.1 Argentina: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.4 Argentina: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.4.1 Argentina: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.4.2 Argentina: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.5 Argentina: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.5.5.3 Rest of South & Central America: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.1 Overview
10.5.5.3.2 Rest of South & Central America: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.3 Rest of South & Central America: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.5.5.3.3.1 Rest of South & Central America: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.4 Rest of South & Central America: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.4.1 Rest of South & Central America: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.4.2 Rest of South & Central America: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.5 Rest of South & Central America: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
11. IMPACT OF COVID-19 PANDEMIC ON IMMUNODIAGNOSTICS MARKET
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
11.4 South & Central America: Impact Assessment of COVID-19 Pandemic
11.5 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
12. GLOBAL IMMUNODIAGNOSTICS MARKET –INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in the Immunodiagnostics Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Abbott Laboratories
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 F. Hoffmann-La Roche Ltd
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 DiaSorin SpA
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Danaher Corp
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Thermo Fisher Scientific Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 PerkinElmer Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 bioMerieux SA
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Svar Life Science AB
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Siemens Healthcare GmbH
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Immunodiagnostics Market – by Product
1.3.2 Global Immunodiagnostics Market – by Clinical Indication
1.3.3 Global Immunodiagnostics Market – by End User
1.3.4 Global Immunodiagnostics Market – by Geography
2. IMMUNODIAGNOSTICS MARKET – KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. IMMUNODIAGNOSTICS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.5 Middle East & Africa PEST Analysis
4.2.6 South & Central America PEST Analysis
4.3 Expert’s Opinion
5. IMMUNODIAGNOSTICS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Prevalence of Infectious Diseases
5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis
6. IMMUNODIAGNOSTICS MARKET – GLOBAL ANALYSIS
6.1 Global Immunodiagnostics Market Revenue Forecast and Analysis
6.2 Global Immunodiagnostics Market, by Geography – Forecast and Analysis
6.3 Market Positioning of Key Players
7. IMMUNODIAGNOSTICS MARKET ANALYSIS – BY PRODUCT
7.1 Overview
7.2 Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
7.3.1 Overview
7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
7.4.1 Overview
7.4.2 Chemiluminescence Immunoassays (CLIA): Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.3 Vitamin D Assay
7.4.3.1 Overview
7.4.3.2 Vitamin D Assay: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.4 HIV Detection
7.4.4.1 Overview
7.4.4.2 HIV Detection: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.5 HIV Ag/Ab Combo assay
7.4.5.1 Overview
7.4.5.2 HIV Ag/Ab Combo Assay: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.6 Other Tests
7.4.6.1 Overview
7.4.6.2 Other Tests: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
7.5.1 Overview
7.5.2 Radioimmunoassays (RIA): Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8. IMMUNODIAGNOSTICS MARKET ANALYSIS – CLINICAL INDICATION
8.1 Overview
8.2 Global Immunodiagnostics Market Share by Clinical Indication - 2022 & 2030 (%)
8.3 Infectious Diseases:
8.3.1 Overview
8.3.2 Infectious Diseases: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 COVID-19
8.3.2.1.1 Overview
8.3.2.1.2 COVID-19: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.2 Tuberculosis
8.3.2.2.1 Overview
8.3.2.2.2 Tuberculosis: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.3 Lyme
8.3.2.3.1 Overview
8.3.2.3.2 Lyme: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.4 Infection Management
8.3.2.4.1 Overview
8.3.2.4.2 Infection Management: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.5 Zika
8.3.2.5.1 Overview
8.3.2.5.2 Zika: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.6 Treponema
8.3.2.6.1 Overview
8.3.2.6.2 Treponema: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.7 TORCH
8.3.2.7.1 Overview
8.3.2.7.2 TORCH: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.8 Measles and Mumps
8.3.2.8.1 Overview
8.3.2.8.2 Measles and Mumps: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.9 VZV
8.3.2.9.1 Overview
8.3.2.9.2 VZV: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.10 EBV
8.3.2.10.1 Overview
8.3.2.10.2 EBV: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
8.4.1 Overview
8.4.2 Hepatitis+HIV: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
8.5.1 Overview
8.5.2 Gastrointestinal: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolics: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
8.7.1 Overview
8.7.2 Endocrinology: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.3 Hypertension
8.7.3.1 Overview
8.7.3.2 Hypertension: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.4 Growth
8.7.4.1 Overview
8.7.4.2 Growth: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.5 Diabetes
8.7.5.1 Overview
8.7.5.2 Diabetes: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.6 Thyroid
8.7.6.1 Overview
8.7.6.2 Thyroid: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.7 Reproductive Endocrinology
8.7.7.1 Overview
8.7.7.2 Reproductive Endocrinology: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9. IMMUNODIAGNOSTICS MARKET ANALYSIS – END USER
9.1 Overview
9.2 Global Immunodiagnostics Market Share by End User - 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
9.6.1 Overview
9.6.2 Academic and Research Institutes: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
10. IMMUNODIAGNOSTICS MARKET – REVENUE AND FORECAST TO 2030 – GEOGRAPHIC ANALYSIS
10.1 North America: Immunodiagnostics Market
10.1.1 Overview
10.1.2 North America: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.1.3 North America: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.3.1 North America: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.4 North America: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.1.4.1 North America: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.4.2 North America: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.5 North America: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.5.1 US: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.1 Overview
10.1.5.1.2 US: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.3 US: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.5.1.3.1 US: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.4 US: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.4.1 US: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.4.2 US: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.5.1.5 US: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.5.2 Canada: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.1 Overview
10.1.5.2.2 Canada: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.3 Canada: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.5.2.3.1 Canada: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.4 Canada: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.4.1 Canada: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.4.2 Canada: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.5.2.5 Canada: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.5.3 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.1 Overview
10.1.5.3.2 Mexico: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.3 Mexico: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.5.3.3.1 Mexico: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.4 Mexico: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.4.1 Mexico: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.4.2 Mexico: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.5.3.5 Mexico: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2 Europe: Immunodiagnostics Market
10.2.1 Overview
10.2.2 Europe: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.2.3 Europe: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.3.1 Europe: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.4 Europe: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.2.4.1 Europe: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.4.2 Europe: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5 Europe: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.1 UK: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.1 Overview
10.2.5.1.2 UK: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.3 UK: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.1.3.1 UK: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.4 UK: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.4.1 UK: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.4.2 UK: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.1.5 UK: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.2 Germany: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.1 Overview
10.2.5.2.2 Germany: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.3 Germany: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.2.3.1 Germany: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.4 Germany: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.4.1 Germany: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.4.2 Germany: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.2.5 Germany: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.3 France: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.1 Overview
10.2.5.3.2 France: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.3 France: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.3.3.1 France: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.4 France: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.4.1 France: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.4.2 France: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.3.5 France: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.4 Italy: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.1 Overview
10.2.5.4.2 Italy: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.3 Italy: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.4.3.1 Italy: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.4 Italy: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.4.1 Italy: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.4.2 Italy: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.4.5 Italy: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.5 Spain: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.1 Overview
10.2.5.5.2 Spain: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.3 Spain: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.5.3.1 Spain: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.4 Spain: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.4.1 Spain: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.4.2 Spain: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.5.5 Spain: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.2.5.6 Rest of Europe: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.1 Overview
10.2.5.6.2 Rest of Europe: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.3 Rest of Europe: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.2.5.6.3.1 Rest of Europe: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.4 Rest of Europe: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.4.1 Rest of Europe: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.4.2 Rest of Europe: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.2.5.6.5 Rest of Europe: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3 Asia Pacific: Immunodiagnostics Market
10.3.1 Overview
10.3.2 Asia Pacific: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.3.3 Asia Pacific: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.3.1 Asia Pacific: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.4 Asia Pacific: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.3.4.1 Asia Pacific: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.4.2 Asia Pacific: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5 Asia Pacific: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.1 China: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.1 Overview
10.3.5.1.2 China: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.3 China: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.1.3.1 China: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.4 China: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.4.1 China: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.4.2 China: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.1.5 China: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.2 Japan: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.1 Overview
10.3.5.2.2 Japan: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.3 Japan: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.2.3.1 Japan: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.4 Japan: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.4.1 Japan: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.4.2 Japan: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.2.5 Japan: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.3 India: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.1 Overview
10.3.5.3.2 India: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.3 India: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.3.3.1 India: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.4 India: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.4.1 India: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.4.2 India: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.3.5 India: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.4 Australia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.1 Overview
10.3.5.4.2 Australia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.3 Australia: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.4.3.1 Australia: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.4 Australia: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.4.1 Australia: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.4.2 Australia: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.4.5 Australia: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.5 South Korea: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.1 Overview
10.3.5.5.2 South Korea: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.3 South Korea: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.5.3.1 South Korea: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.4 South Korea: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.4.1 South Korea: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.4.2 South Korea: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.5.5 South Korea: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.3.5.6 Rest of Asia Pacific: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.1 Overview
10.3.5.6.2 Rest of Asia Pacific: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.3 Rest of Asia Pacific: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.3.5.6.3.1 Rest of Asia Pacific: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.4 Rest of Asia Pacific: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.4.1 Rest of Asia Pacific: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.4.2 Rest of Asia Pacific: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.3.5.6.5 Rest of Asia Pacific: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4 Middle East & Africa: Immunodiagnostics Market
10.4.1 Overview
10.4.2 Middle East & Africa: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.4.3 Middle East & Africa: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.3.1 Middle East & Africa: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.4 Middle East & Africa: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.4.4.1 Middle East & Africa: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.4.2 Middle East & Africa: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5 Middle East & Africa: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4.5.1 UAE: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.1 Overview
10.4.5.1.2 UAE: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.3 UAE: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.5.1.3.1 UAE: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.4 UAE: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.4.1 UAE: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.4.2 UAE: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5.1.5 UAE: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4.5.2 Saudi Arabia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.1 Overview
10.4.5.2.2 Saudi Arabia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.3 Saudi Arabia: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.5.2.3.1 Saudi Arabia: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.4 Saudi Arabia: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.4.1 Saudi Arabia: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.4.2 Saudi Arabia: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5.2.5 Saudi Arabia: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4.5.3 South Africa: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.1 Overview
10.4.5.3.2 South Africa: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.3 South Africa: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.5.3.3.1 South Africa: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.4 South Africa: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.4.1 South Africa: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.4.2 South Africa: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5.3.5 South Africa: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.4.5.4 Rest of Middle East & Africa: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.1 Overview
10.4.5.4.2 Rest of Middle East & Africa: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.3 Rest of Middle East & Africa: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.4.5.4.3.1 Rest of Middle East & Africa: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.4 Rest of Middle East & Africa: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.4.1 Rest of Middle East & Africa: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.4.2 Rest of Middle East & Africa: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.4.5.4.5 Rest of Middle East & Africa: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.5 South & Central America: Immunodiagnostics Market
10.5.1 Overview
10.5.2 South & Central America: Immunodiagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.5.3 South & Central America: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.5.3.1 South & Central America: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.5.4 South & Central America: Immunodiagnostics Market, by Clinical Indication – 2020–2030 (US$ Million)
10.5.4.1 South & Central America: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.5.4.2 South & Central America: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.5.5 South & Central America: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.5.5.1 Brazil: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.1 Overview
10.5.5.1.2 Brazil: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.3 Brazil: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.5.5.1.3.1 Brazil: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.4 Brazil: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.4.1 Brazil: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.4.2 Brazil: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.5.5.1.5 Brazil: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.5.5.2 Argentina: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.1 Overview
10.5.5.2.2 Argentina: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.3 Argentina: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.5.5.2.3.1 Argentina: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.4 Argentina: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.4.1 Argentina: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.4.2 Argentina: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.5.5.2.5 Argentina: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.5.5.3 Rest of South & Central America: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.1 Overview
10.5.5.3.2 Rest of South & Central America: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.3 Rest of South & Central America: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.5.5.3.3.1 Rest of South & Central America: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.4 Rest of South & Central America: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.4.1 Rest of South & Central America: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.4.2 Rest of South & Central America: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.5.5.3.5 Rest of South & Central America: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
11. IMPACT OF COVID-19 PANDEMIC ON IMMUNODIAGNOSTICS MARKET
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
11.4 South & Central America: Impact Assessment of COVID-19 Pandemic
11.5 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
12. GLOBAL IMMUNODIAGNOSTICS MARKET –INDUSTRY LANDSCAPE
12.1 Overview
12.2 Growth Strategies in the Immunodiagnostics Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. COMPANY PROFILES
13.1 Abbott Laboratories
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 F. Hoffmann-La Roche Ltd
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 DiaSorin SpA
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Danaher Corp
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Thermo Fisher Scientific Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 PerkinElmer Inc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 bioMerieux SA
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Svar Life Science AB
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Siemens Healthcare GmbH
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Infectious Diseases and Funding
Table 2. North America Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Im
Table 1. Infectious Diseases and Funding
Table 2. North America Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Im
